Comparative Pharmacovigilance Analysis of Safety Signals Among Advanced Prostate Cancer Therapies Using FAERS (FDA Adverse Event Reporting System).
This study reveals that cabazitaxel and abiraterone have significant safety signals, while other therapies did not show detected signals, which should not be interpreted as evidence of safety.
Where it sits
this study against the rest of the vipivotide corpusSummary and findings
This study analyzed adverse events associated with various advanced prostate cancer therapies using the FDA Adverse Event Reporting System. It included drugs such as enzalutamide, darolutamide, and lutetium-177 vipivotide among others. The findings highlighted distinct toxicity profiles and identified significant safety signals for specific therapies.
Abstract
Therapeutic options for advanced prostate cancer have expanded in recent years, incorporating multiple-system treatment approaches with differing mechanisms of action. However, comparative real-world safety data following drug approval remain limited. As such, the aim of this study is to characterize adverse events and disproportionate safety signals among advanced prostate cancer therapies using the FDA Adverse Event Reporting System (FAERS). A retrospective pharmacovigilance study of FAERS reports evaluated enzalutamide, darolutamide, apalutamide, abiraterone acetate, relugolix, niraparib/abiraterone, talazoparib, rucaparib, cabazitaxel, sipuleucel-T, and lutetium-177 vipivotide. Adverse events were categorized by System Organ Class and Preferred Terms. Reporting odds ratios (RORs) with 95% confidence intervals identified safety signals. Among 172,440 reports, most involved patients aged 65-85 years. Cabazitaxel had the highest proportion of serious reports (86.6%) and deaths (22%), whereas relugolix had the lowest (23.3% and 4.8%). Nervous system disorders predominated with enzalutamide and darolutamide, gastrointestinal disorders with abiraterone, rucaparib, and niraparib/abiraterone, and hematologic toxicities with cabazitaxel, talazoparib, and lutetium-177 vipivotide. Significant safety signals were identified for abiraterone and cabazitaxel, but not other therapies. The absence of a detected signal should not be interpreted as evidence of safety or equivalence, as reporting volume, detection bias, and statistical power varied across therapies. Overall, the therapies demonstrated distinct toxicity profiles, which may inform treatment selection, toxicity monitoring, and patient counseling.
Background
This paper addresses the comparative safety of advanced prostate cancer therapies, a critical area given the recent expansion of treatment options. Prior studies have indicated variability in adverse event profiles among cancer therapies, but comprehensive real-world safety data post-approval remain sparse. Understanding these safety signals is essential for clinicians in making informed treatment decisions.
Methods
A retrospective pharmacovigilance study was conducted using FDA Adverse Event Reporting System (FAERS) data. The analysis included reports for multiple therapies including lutetium-177 vipivotide, with a total of 172,440 reports evaluated. Adverse events were categorized by System Organ Class and Preferred Terms, and reporting odds ratios (RORs) were calculated to identify safety signals.
Results
Among the 172,440 reports, cabazitaxel had the highest proportion of serious reports at 86.6% and deaths at 22%. Relugolix had the lowest proportions of serious reports and deaths at 23.3% and 4.8%, respectively. Significant safety signals were identified for abiraterone and cabazitaxel, while no signals were detected for other therapies.
Interpretation
The findings indicate that cabazitaxel and abiraterone are associated with higher rates of serious adverse events compared to other therapies. While the statistical significance of these findings is noted, the clinical significance may vary, and the absence of signals for other therapies does not imply safety. Confounding factors such as reporting volume and detection bias limit the conclusions that can be drawn.
Key findings
- 86.6% serious reports for cabazitaxel, n=172440.
- 22% deaths associated with cabazitaxel, n=172440.
- 4.8% deaths associated with relugolix, n=172440.
- Nervous system disorders predominated with enzalutamide and darolutamide.
- Significant safety signals identified for abiraterone and cabazitaxel.
Limitations
- Retrospective analysis may introduce reporting bias.
- Data from FAERS does not establish causality.
- Variation in reporting volume and statistical power across therapies.